HPV 16 and its role in the development of cervical cancer: prevention, diagnosis and treatment

Katarzyna Łysiak; Anna Łysiak

doi:10.56782/pps.381

Published : 2025-08-07

No. 2025 (Early Access)

HPV 16 and its role in the development of cervical cancer: prevention, diagnosis and treatment

Katarzyna Łysiak

Anna Łysiak

DOI: https://doi.org/10.56782/pps.381

Abstract

Human papillomavirus type 16 (HPV 16) is the most oncogenic and one of the most common genotypes of human papillomavirus. Its oncogenic properties make it play a key role in the development of many cancers, including cervical, throat, anal and other malignant tumors. The main route of HPV infection is sexual contact. This article characterizes the HPV 16 virus and its unique oncogenic properties. The epidemiology of infections and preventive strategies, including vaccinations and screening programs, which have significantly reduced the number of cases of HPV-related cancers, are discussed. Modern diagnostic methods, such as genetic tests and cytology, which enable early detection of infections and precancerous lesions, are also presented. The article also addresses the issues of treatment of lesions caused by HPV 16, including local therapies used in the case of precancerous lesions and comprehensive methods of treating advanced cancers. The last part discusses research perspectives, such as the development of new vaccines and immunotherapy, which may play a key role in the fight against this virus in the future. This article highlights the importance of an interdisciplinary approach to the prevention, diagnosis, and treatment of HPV 16 infections, which is essential to reducing the global burden of cancers associated with this virus.

Keywords:

HPV 16, cervical cancer, cytology, vaccine

Most read articles by the same author(s)

Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Julia Ignacak, Kinga Ściurka, Mikołaj Borek, Oliwia Grzelak, Insomnia in the elderly and contemporary treatment methods , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, The role of the gut microbiome in Alzheimer's disease , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Kinga Ściurka, Julia Ignacak, Mikołaj Borek, Oliwia Grzelak, Nausea and vomiting associated with chemotherapy and principles of management in their prevention , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Magdalena Makarewicz, Anna Łysiak, Katarzyna Łysiak, Barbara Maziarz, Evaluation of the effectiveness of platelet-rich plasma therapy in the treatment of osteoarthritis compared to other treatment methods , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Kinga Ściurka, Julia Ignacak, Mikołaj Borek, The use of botulinum toxin in ophthalmology , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)

Similar Articles

Esraa Alkhalil, Bashar Jarad, Tala Saleh, Wafaa Aldarwish, Dr. Dima Joujeh, BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Teresa Żołek, Aleksandra Trzeciak, THE MECHANISM OF ACTION OF INDOLE-3-CARBINOL AND 3,3´-DIINDOLYLMETHANE IN CANCER CHEMOPREVENTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 2 (2017)
Magdalena Wojtczuk, Agnieszka Dominiak, Carnosic Acid in Carcinogenesis: From Theory to Practice , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Agata Pisula, Agnieszka Sienicka, Agnieszka Dobrowolska-Redo, Joanna Kacperczyk-Bartnik, Ewa Romejko-Wolniewicz, PARP inhibitors in ovarian cancer therapy , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Ewelina Flegiel, Magdalena Piotrowska, Magdalena Ptasznik, Aleksandra Baran, Justyna Lenart, Miłosz Podrażka, Joanna Mazurek, Hubert Stachowicz, Weronika Bartos, Monika Adamczyk, Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Uzma Faridi, Anti-cancer activity of phenyl-1,3,5-heptatriyne in human liver cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, Barbara Maziarz, Paulina Przywara, Natalia Bogumiłło, Kinga Ściurka, Julia Ignacak, Mikołaj Borek, Oliwia Grzelak, Nausea and vomiting associated with chemotherapy and principles of management in their prevention , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Paweł Żero, Maria Niemyjska, Magdalena Rasztawicka, Dorota Maciejewska, BREAST CANCER DISEASE AND NEW COMPOUNDS WITH ANTICANCER ACTIVITY , Prospects in Pharmaceutical Sciences: Vol. 3 No. 2 (2005)
Kinga Byk, Filip Charuk, Ewa Olędzka, Marcin Sobczak, Monika Zielińska-Pisklak, CLINICAL APPLICATIONS OF PACLITAXEL IN CANCER THERAPY , Prospects in Pharmaceutical Sciences: Vol. 19 No. 2 (2021)
Magdalena Bamburowicz-Klimkowska, Mirosław M. Szutowski, STRATEGIES TO COMBAT MULTIDRUG RESISTANCE OF CANCER , Prospects in Pharmaceutical Sciences: Vol. 10 No. 1 (2012)

1 2 3 4 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Łysiak, K., & Łysiak, A. (2025). HPV 16 and its role in the development of cervical cancer: prevention, diagnosis and treatment. Prospects in Pharmaceutical Sciences, (2025 (Early Access). https://doi.org/10.56782/pps.381

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Yousefi, Z.; Aria, H.; Ghaedrahmati, F.; et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front. Immunol. 2022, 12. Art. No: 805695. DOI: 10.3389/fimmu.2021.805695 DOI: https://doi.org/10.3389/fimmu.2021.805695

2. Nelson, C.W.; Mirabello, L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023, 15, Art.. No: 200258. DOI: 10.1016/j.tvr.2023.200258 DOI: https://doi.org/10.1016/j.tvr.2023.200258

3. Demarco, M.; Hyun, N.; Carter-Pokras, O.; et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. eClinicalMedicine. 2020, 22, Art. No: 100293. DOI: 10.1016/j.eclinm.2020.100293 DOI: https://doi.org/10.1016/j.eclinm.2020.100293

4. Baedyananda, F.; Sasivimolrattana, T.; Chaiwongkot, A.; et al. Role of HPV16 E1 in cervical carcinogenesis. Front. Cell Infect. Microbiol. 2022, 12, Art. No: 955847. DOI: 10.3389/fcimb.2022.955847 DOI: https://doi.org/10.3389/fcimb.2022.955847

5. Yu, L.; Majerciak, V.; Zheng, Z.M. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int. J. Mol. Sci. 2022, 23, p. 4943. DOI: 10.3390/ijms23094943 DOI: https://doi.org/10.3390/ijms23094943

6. Muñoz, N.; Bosch, F.X.; de Sanjosé, S.; et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, pp: 518–527. DOI: 10.1056/NEJMoa021641 DOI: https://doi.org/10.1056/NEJMoa021641

7. Mikuličić, S.; Strunk, J.; Florin, L. HPV16 Entry into Epithelial Cells: Running a Gauntlet. Viruses. 2021, 13, p. 2460. DOI: 10.3390/v13122460 DOI: https://doi.org/10.3390/v13122460

8. Moody, C.A. Mechanisms by which HPV Induces a Replication Competent Environment in Differentiating Keratinocytes. Viruses. 2017, 9, p: 261. DOI: 10.3390/v9090261 DOI: https://doi.org/10.3390/v9090261

9. Shaikh, F.; Sanehi, P.; Rawal, R. Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. Bioinformation. 2012, 8, pp. 607-612. DOI: 10.6026/97320630008607 DOI: https://doi.org/10.6026/97320630008607

10. Broniarczyk, J.; Koczorowska, M. M.; Durzyńska, J.; Warowicka, A.; Goździcka-Józefiak, A. Struktura i właściwości wirusa brodawczaka ludzkiego [Structure and properties of human papillomavirus]. Biotechnologia. 2010, 90, pp. 126-145. DOI: 10.18388/biotech.2010.90.126.

11. Piesiaków, M. L.; Imko-Walczuk, B.; Osiecka, B.; Sławińska, D.; Sławiński, M. Wirusy onkogenne w etiopatogenezie nowotworów skóry u chorych po przeszczepieniach narządów. [Carcinogenic viruses in etiopathogenesis of skin cancers in patients after organ transplantation.] Postępy Hig. Med. Dosw. 2016, 70, pp. 1256-1265. DOI: 10.5604/17322693.1226494. DOI: https://doi.org/10.5604/17322693.1194807

12. Warowicka, A.; Nawrot, R.; Broniarczyk, J.; Węglewska, M.; Goździcka-Józefiak, A. Wirusy onkogenne a nowotwory. [Oncogenic viruses and cancer]. Postępy Biochemii. 2020, 66, pp.385-394. DOI: 10.18388/pb.2020_360. DOI: https://doi.org/10.18388/pb.2020_360

13. Rafael,T. S.; Rotman, J.; Brouwer, O. R.; Poel, H. G.; Mom, C. H.; Kenter, G. G.; Gruijl, T. D.;Jordanova, E. S. Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. J. Clin. Med. 2022, 11, pp: 1101; DOI: 10.3390/jcm11041101 DOI: https://doi.org/10.3390/jcm11041101

14. Zhou, C.; Toung, Z. K.; Frazer, I. H. Papillomavirus Immune Evasion Strategies Target the Infected Cell. Frontier in Immunology. 2019, 9, pp. 682. DOI: 10.3389/fonc.2019.00682. DOI: https://doi.org/10.3389/fonc.2019.00682

15. Senba, M.; Mori, N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol. Rev. 2012, 6. DOI: 10.4081/oncol.2012.e17 DOI: https://doi.org/10.4081/oncol.2012.e17

16. Williamson, A.L. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. 2023, 15, p. 1440. DOI: 10.3390/v15071440 DOI: https://doi.org/10.3390/v15071440

17. Zou, K.; Huang, Y.; Li, Z. Prevention and treatment of human papillomavirus in men benefits both men and women. Front. Cell. Infect. Microbiol. 2022, 12, Art. No: 1077651. DOI: 10.3389/fcimb.2022.1077651 DOI: https://doi.org/10.3389/fcimb.2022.1077651

18. Kechagias, K.S.; Kalliala, I.; Bowden, S.J.; et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ. 2022, Art. No: 378:e070135. DOI: 10.1136/bmj-2022-070135 DOI: https://doi.org/10.1136/bmj-2022-070135

19. Eriksen, D.O.; Jensen, P.T.; Schroll, J.B.; Hammer, A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta‐analysis. Acta. Obstet. Gynecol. Scand. 2022, 101, pp: 597–607. DOI: 10.1111/aogs.14359 DOI: https://doi.org/10.1111/aogs.14359

20. Malagon, T.; MacCosham, A.; Burchell, A.N.; El-Zein, M.; et al. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clin. Infect. Dis. 2021, 75, pp:365–371. DOI: 10.1093/cid/ciab985 DOI: https://doi.org/10.1093/cid/ciab985

21. Lin, R.; Jin, H.; Fu, X. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis. Expert. Rev. Vaccines. 2023, 22, pp. 1168-1178. DOI: 10.1080/14760584.2023.2287135 DOI: https://doi.org/10.1080/14760584.2023.2287135

22. Human Papillomavirus Vaccines WHO: WHO Position. Wkly. Epidemiol. Rec. 2022, 97, pp: 645–672.

23. Brisson, M.; Bénard, É.; Drolet, M.; Bogaards, J.A.; Baussano, I.; et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016, 1, pp: 8–17. DOI: 10.1016/S2468-2667(16)30001-9 DOI: https://doi.org/10.1016/S2468-2667(16)30001-9

24. Gultekin, M.; Ramirez, P.T.; Broutet, N.; Hutubessy, R. World Health Organization call for action to eliminate cervical cancer globally. Int. J. Gynecol. Cancer. 2020, 30, pp: 426–427. DOI: 10.1136/ijgc-2020-001285 DOI: https://doi.org/10.1136/ijgc-2020-001285

25. Glinska, P.; Komerska, K.; Janik,B.; et al. HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial. BMC Cancer. 2023, 23, p:1118. DOI: 10.1186/s12885-023-11597-5 DOI: https://doi.org/10.1186/s12885-023-11597-5

26. Open Research. Available online: https://openbadania.pl/educations/article/bezpieczny-seks-i-profilaktyka-raka-szyjki-macicy (accessed 10.01.2025)

27. Repp, K.K.; Nielson, C.M.; Fu, R.; et al. Male Human Papillomavirus Prevalence and Association With Condom Use in Brazil, Mexico, and the United States. J. Infect. Dis. 2012, 205, pp: 1287–1293. DOI: 10.1093/infdis/jis181 DOI: https://doi.org/10.1093/infdis/jis181

28. Chih, H.J.; Lee, A.H.; Colville, L.; et al. A review of dietary prevention of human papillomavirus-related infection of the cervix and cervical intraepithelial neoplasia. Nutr. Cancer. 2013, 65, pp: 317-28. DOI: 10.1080/01635581.2013.757630 DOI: https://doi.org/10.1080/01635581.2013.757630

29. Irish, L.A.; Kline, C.E.; Gunn, H.E.; et al. The role of sleep hygiene in promoting public health: A review of empirical evidence. Sleep. Med. Rev. 2015, 22, pp: 23-36. DOI: 10.1016/j.smrv.2014.10.001. Epub 2014 Oct 16 DOI: https://doi.org/10.1016/j.smrv.2014.10.001

30. Coker, A.L.; Bond, S.; Madeleine, M.M.; Luchok, K.; Pirisi, L. Psychosocial stress and cervical neoplasia risk. Psychosom. Med. 2003, 65, pp: 644-651. DOI: 10.1097/01.psy.0000041471.57895.08 DOI: https://doi.org/10.1097/01.PSY.0000041471.57895.08

31. Batman, A.M.; Miles, M.F. Translating Alcohol Research Opportunities and Challenges. Alcohol Res. Curr. Rev. 2015, 37, pp: 7-14. DOI: 10.35946/arcr.v37.2.01

32. Schabath, M.B.; Villa, L.L.; Lin, H.Y.; et al. A prospective analysis of smoking and human papillomavirus (HPV) infection among men in The HPV in Men (HIM) Study. Int. J. Cancer. 2013, 134, pp: 2448–2457. DOI: 10.1002/ijc.28567 DOI: https://doi.org/10.1002/ijc.28567

33. Practical Medicine. Available online: https://www.mp.pl/pacjent/ginekologia/badania-i-zabiegi/292320,cytologia-badanie-cytologiczne-wszystko-co-musisz-wiedziec?fbclid=IwY2xjawH-SbJleHRuA2FlbQIxMAABHX6xPNPHf7-jSY4DldjDCodgkJ_xpP41BulPH3ciEKfrBcV2Qo_ZqcQmFg_aem_keKq1B96e0t7imn09u63ng (accessed 14.01.2025)

34. Walboomers, J.M.; Jacobs, M.V.; Manos, M.M.; et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, pp: 12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F DOI: https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

35. World Health Organization. Available online: https://www.who.int/europe/news-room/11-09-2021-who-recommends-dna-testing-as-a-first-choice-screening-method-for-cervical-cancer-prevention?fbclid=IwY2xjawIE3XdleHRuA2FlbQIxMAABHRZ-c0BV7Dsw1jOjYqWCW5zHQV5Ngtso4U4AN__NG_4qYmwbl42sbMEFgQ_aem_xAjJJ314fcphN8BKWl1hCA (accessed 16.01.2025)

36. Ronco, G.; Giorgi-Rossi, P.; Carozzi, F.; et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet. Oncol. 2010, 11, pp: 249-257. DOI: 10.1016/S1470-2045(09)70360-2 DOI: https://doi.org/10.1016/S1470-2045(09)70360-2

37. Zheng, Z.; Yang, X.; Yao, X.; Li, L. Prognostic value of HPV 16/18 genotyping and geminin mRNA quantification in low-grade cervical squamous intraepithelial lesion. Bioengineered. 2021, 12, pp. 11482-11489. DOI: 10.1080/21655979.2021.2009959 DOI: https://doi.org/10.1080/21655979.2021.2009959

38. Stoler, M.H.; Wright Jr, T.C.; Parvu, V.; Yanson, K.; et al. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology. Am. J. Clin. Pathol. 2019, 151, pp: 433-442. DOI: 10.1093/ajcp/aqy169 DOI: https://doi.org/10.1093/ajcp/aqy169

39. Torres-Ibarra, L.; Cuzick, J.; Lorincz, A.; Spiegelman, D.; et al. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico. JAMA Netw. Open. 2019, 2, Art. No: e1915781. DOI: 10.1001/jamanetworkopen.2019.15781 DOI: https://doi.org/10.1001/jamanetworkopen.2019.15781

40. Singh, M.; Mockler, D.; Akalin, A.; et al. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma. Cancer Cytopathol. 2012, 120, pp: 26-34. DOI: 10.1002/cncy.20188 DOI: https://doi.org/10.1002/cncy.20188

41. Wentzensen, N.; Schwartz, L.; Zuna, R.E.; et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin. Cancer Res. 2012, 18, pp: 4154-4162. DOI: 10.1158/1078-0432.CCR-12-0270 DOI: https://doi.org/10.1158/1078-0432.CCR-12-0270

42. Bergeron, C.; Ronco, G.; Reuschenbach, M.; et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int. J. Cancer. 2015, 136, pp:2741-2751. DOI: 10.1002/ijc.28900 DOI: https://doi.org/10.1002/ijc.28900

43. Bruno, M.T.; Guaita, A.; Boemi, S.; et al. Performance of p16/Ki67 Immunostaining for Triage of Elderly Women with Atypical Squamous Cells of Undetermined Significance. J. Clin. Med. 2023, 12, p. 3400. DOI: 10.3390/jcm12103400 DOI: https://doi.org/10.3390/jcm12103400

44. McMenamin, M.; McKenna, M.; et al. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening. Am. J. Clin. Pathol. 2018, 150, pp: 512-521. DOI: 10.1093/ajcp/aqy073 DOI: https://doi.org/10.1093/ajcp/aqy073

45. Practical Medicine. Available online: https://www.mp.pl/pacjent/badania_zabiegi/263494,kolposkopia (accessed 15.01.2025)

46. Cervix. Available online: https://kolposkopia.com/kolposkopia/?fbclid=IwY2xjawIDK45leHRuA2FlbQIxMAABHfQDWAWzt2m_tpKfwrl6PDpx95nB2Ql1U3WWfN4589kOvDYyMPzYA3IiIQ_aem_4Yy-EPbcRutHsHQqKFzZtg (accessed 20.01.2025)

47. Wikipedia. The free encyclopedia. Available online: https://pl.wikipedia.org/wiki/Pr%C3%B3ba_Schillera?fbclid=IwY2xjawIDK-FleHRuA2FlbQIxMAABHXTU8oF5GepS_Ug53zjApbUmTavBBlauQzjbCCX3S9WCeLNON1jWgs1yrA_aem_koL1sszZC7bNj6ONdHhMJw (accessed 20.01.2025)

48. Service of the Republic of Poland. Available online: https://www.gov.pl/web/zdrowie/program-profilaktyki-raka-szyjki-macicy-cytologia-?fbclid=IwY2xjawH-SaZleHRuA2FlbQIxMAABHUeDbNySpsxHsIaHwKRjGjM_7LQTvlNJfq61qbXlCMXAVTvAzi2rRJNmUQ_aem_DJ7a5-NoYaVjImmdthlnZA (accessed 16.01.2025)

49. Service of the Republic of Poland. Available online: https://www.gov.pl/web/zdrowie/dwa-nowoczesne-badania-w-profilaktyce-raka-szyjki-macicy?fbclid=IwY2xjawH-ScNleHRuA2FlbQIxMAABHT59ROhJPA9T8XZe6qXhU9n6F3c0v7rwSxkV9ImGXXwVzteEsN6qtlwB3g_aem_PC65Pv_PXaFzq7Jgfdr9Mw (accessed 16.01.2025)

50. Jach, R.; Mazurec, M.; Trzeszcz, M.; Stukan, M.; et al. Position on the Scheme of Procedure for Basic Cervical Cancer Screening of the Polish Society of Gynecologists and Obstetricians (PTGiP) – June 2022. Position of the Polish Society of Colposcopy and Cervical Pathophysiology – August 2022. Practical Medicine – Gynecology and obstetrics. 2022, pp. 69-82.

51. Kornovski, Y.; Slavchev, S.; Kostov, S.; et al. Precancerous lesions of the cervix — aetiology, classification, diagnosis, prevention. Oncol. Clin. Pract. 2021, 17. DOI: 10.5603/OCP.2021.0027 DOI: https://doi.org/10.5603/OCP.2021.0027

52. Tai, Y. J.; Chen, Y. Y.; Hsu, H. C.; Chiang, C. J.; You, S. L.; Chen, H. C.; Chen, C. A.; Cheng, W. F. Clinical management and risk reduction in women with low-grade squamous intraepithelial lesion cytology: A population-based cohort study. PLoS. One. 2017, 12. DOI: 10.1371/journal.pone.0188203 DOI: https://doi.org/10.1371/journal.pone.0188203

53. Scheungraber, C.; Kleekamp, N.; Schneider, A. Management of low-grade squamous intraepithelial lesions of the uterine cervix. Br. J Cancer. 2004 90, pp: 975–978. DOI: 10.1038/sj.bjc.6601415 DOI: https://doi.org/10.1038/sj.bjc.6601415

54. Pisarska-Krawczyk, M.; Radomski, D.; Jarząbek-Bielecka, G.; Mizgier, M.; Kędzia, W. Cryotherapy and other ablation techniques in the treatment of cervical intraepithelial neoplasia. [Krioterapia a inne metody ablacyjne w leczeniu śródnabłonkowej neoplazji szyjki macicy]. Curr. Gynecol. Oncol. 2015, 13, pp: 165–171 DOI: 10.15557/CGO.2015.0018 DOI: https://doi.org/10.15557/CGO.2015.0018

55. Center for Preventive Medicine. Mental health. Cervical cryotherapy. Available online: https://cmp.krakow.pl/prywatna/uslugi/poradnia-ginekologiczno-poloznicza/krioterapia-szyjki-macicy/ (accessed on 29 January 2025)

56. World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Available online: https://www.who.int/publications/i/item/9789241550598 (accessed on 29 January 2025).

57. de Fouw, M.; Oosting, R. M.; Rutgrink, A.; Dekkers, O. M.; Peters, A. A. W.; Beltman, J. A systematic review and meta-analysis of thermal coagulation compared with cryotherapy to treat precancerous cervical lesions in low- and middle-income countries. Int. J. Gynaecol. Obstet. 2019, 147, pp: 14-18 DOI: https://doi.org/10.1002/ijgo.12904

58. Oncogin Gynecology. Surgical fractional laser. Available online: http://onkogin.pl/laser-frakcyjny-chirurgiczny/ (accessed on 29 January 2025).

59. La Guèl Clinic & SPA. LEEP – elektrokonizacja szyjki macicy w przypadku zmian HSIL. Available online: https://www.laguel.pl/leep-elektrokonizacja-szyjki-macicy-w-przypadku-zmian-hsil/ (accessed on 29 January 2025).

60. Martin-Hirsch, P. P. L.; Paraskevaidis, E.; Bryant, A.; Dickinson, H. O.; Keep, S. L. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010, 6. DOI: 10.1002/14651858.CD001318.pub2 DOI: https://doi.org/10.1002/14651858.CD001318.pub2

61. Li, X.; Liu, M.; Ji, Y.; Qu, P. The effectiveness of cold-knife conization (CKC) for post-menopausal women with cervical high-grade squamous intraepithelial lesion: a retrospective study. BMC Surg. 2021, 21, pp: 241. DOI: 10.1186/s12893-021-01238- DOI: https://doi.org/10.1186/s12893-021-01238-8

62. StatPearls. Publishing. Cold Knife Conization of the Cervix. Available online: https://www.ncbi.nlm.nih.gov/books/NBK441845/ (accessed on 29 January 2025).

63. Burmeister, C. A.; Khan, S. F.; Schäfer, G.; Mbatani, N.; Adams, T.; Moodley, J.; Prince, S. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022, 13. DOI: 10.1016/j.tvr.2022.200238 DOI: https://doi.org/10.1016/j.tvr.2022.200238

64. National Library of Medicine. Cervical Cancer Treatment. Available online: https://www.ncbi.nlm.nih.gov/books/NBK65985/ (accessed on 30 January 2025).

65. Tewari, K. S.; Sill, M. W.; Penson, R. T.; Huang, H.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J.; Leitao, M. M.; Michael, H. E.; DiSaia, P. J.; Copeland, L. J.; Creasman, W. T.; Stehman, F. B.; Brady, M. F.; Burger, R. A.; Thigpen, J. T.; Birrer, M. J.; Waggoner, S. E.; Moore, D. H.; Look, K. Y.; Koh, W. J.; Monk, B. J. Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Lancet. 2017, 390, pp: 1654–1663. DOI: 10.1016/S0140-6736(17)31607-0. DOI: https://doi.org/10.1016/S0140-6736(17)31607-0

66. Nowak-Markwitz, E.; Basta, A.; Kotarski, J.; Markowska, J.; Oszukowski, P.; Sajdak, S.; Sawicki, W.; Spaczyński, M. Systemic therapy of recurrent or persistent cancer of the cervix. Recommendations of the Polish Gynecological Society [Rekomendacje Polskiego Towarzystwa Ginekologicznego. Leczenie systemowe nawrotowego i przetrwałego raka szyjki macicy]. Ginekol Pol. 2015, 86, pp: 712-714. DOI: 10.17772/gp/59225. DOI: https://doi.org/10.17772/gp/59225

67. Massobrio, R.; Bianco, L.; Campigotto, B.; Attianese D.; Maisto, E.; Pascotto, M.; Redda, M. G. R.; Ferrero, A. New Frontiers in Locally Advanced Cervical Cancer Treatment. J. Clin. Med. 2024, 13, pp: 4458. DOI: 10.3390/jcm13154458. DOI: https://doi.org/10.3390/jcm13154458

68. Mo, Y.; Ma, J.; Zhang, H.; Shen, J.; Chen, J.; Hong, J.; Xu, Y.; Qian, C. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front. Cell Infect. Microbiol. 2022, 12, pp: 909223. DOI: 10.3389/fcimb.2022.909223 DOI: https://doi.org/10.3389/fcimb.2022.909223

69. Rumfield, C. S.; Roller, N.; Pellom, S. T.; Jeffrey, S.; Jochems, C. Therapeutic Vaccines for HPV-Associated Malignancies. Immunotargets Ther. 2020, 9, pp: 167–200. DOI: 10.2147/ITT.S273327 DOI: https://doi.org/10.2147/ITT.S273327

70. Trimble, C. L.; Morrow, M. P.; Kraynyak, K. A.; Shen, X.; Dallas, M. et all. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015, 386, pp: 2078–2088. DOI: 10.1016/S0140-6736(15)00239-1 DOI: https://doi.org/10.1016/S0140-6736(15)00239-1

71. Teffera, Z.; Yihunie, W.; Tegegne, B.; Misganaw, B.; Abebaw, D.; Belayineh, M.; Akelew, Y.; Dilnesa, T.; Adugna, A.; Silabat, B.; Tefera, S.; Belew, H.; Bimrew, L. Efficacy of a novel high risk HPV 16/18 therapeutic vaccine in treating cervical intraepithelial neoplasia and cervical cancer in a clinical trial: A systematic review and meta analysis. World Academy of Sciences Journal, 2024, 6, pp: 52. DOI: 10.3892/wasj.2024.267 DOI: https://doi.org/10.3892/wasj.2024.267

Katarzyna Łysiak

kas.lysiak@gmail.com

Affiliation:

a:1:{s:5:"en_US";s:140:"Stefan Cardinal Wyszynski Provincial Specialist Hospital Independent Public Health Care Center in Lublin, al. Kraśnicka 100, 20-718 Lublin ";} Poland

Anna Łysiak

ann.lysiak@gmail.com

Affiliation:

2 Independent Public Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-954 Lublin Poland